Management Team

Daniel G. Stokely has more than 30 years of experience in finance and accounting. Daniel began his career at Deloitte & Touche and since that time, he has spent the majority of his career in positions of financial leadership within both publicly traded and privately-held pharmaceutical companies. Most recently, since 2012, Daniel served as Executive Vice President and Chief Financial Officer of Sentynl Therapeutics Inc., a privately-held specialty pharmaceutical company focused on in-licensing, acquisition, marketing and distribution of development stage and commercially marketed prescription pain products, which was sold to Cadila Healthcare Ltd. in January 2017. From 2004 to 2012, Daniel served as Vice President of Finance and Chief Accounting Officer of Victory Pharma, a privately-held specialty pharmaceutical company focused on in-licensing, internal product development, marketing and distribution of pain specialty products, which was sold to Shionogi, Inc., a Japanese pharmaceutical company, in 2011. From 2001 to 2004, Daniel served as the Corporate Controller and Chief Accounting Officer for Wireless Facilities, Inc. (currently Kratos Defense & Security Solutions), a publicly traded, global provider of communications and security services for the wireless communications industry. From 1994 to 2001, Daniel served as Corporate Controller of Dura Pharmaceuticals, a publicly traded pharmaceutical company that was sold to Elan Pharmaceuticals in late 2000. Daniel has a bachelor’s degree in accounting from San Diego State University and is a Certified Public Accountant (licensed in California).

Dr. Howard Levy has over 30 years of experience in the pharmaceutical industry, working with both public and private biotechnology companies on clinical and drug development strategy and execution. He was most recently Chief Medical Officer of Catalyst Biosciences, Inc. Prior to that, Dr. Levy was the Senior Global Medical Program Director at CSL Behring; Senior Vice President and Chief Medical Officer at Inspiration Biopharmaceuticals; Chief Medical Officer at Sangart, Inc.; Associate Vice President, Clinical Research, Medical and Regulatory Affairs, at Novo Nordisk; Clinical Research Physician and Medical Director, Acute Care in the U.S. Medical Division of Eli Lilly and Company. He was also Chief of Critical Care Medicine at the University of New Mexico in Albuquerque for 11 years.

Dr. Levy holds M.B.B.Ch. and Ph.D. degrees from University of the Witwatersrand in Johannesburg, South Africa, and a M.M.M. from Carnegie Mellon University’s H. John Heinz III College.

Laura Goldberg has more than 20 years’ experience in the pharmaceutical, medical device and biotech industry, with expertise in commercialization, taking products from the clinical research stage to regulatory commercial approval.

Goldberg joined Ampio in 2014 responsible for developing the company’s quality management system, validation, and quality control methods as Ampio moved drug product manufacturing into the new facility in Englewood, Colorado. She is responsible for quality assurance, quality control, regulatory, and advancing scientific discovery with a focus on regulatory approval, scientific strategy, clinical trial design, and market expansion opportunities.

Before joining Ampio, Goldberg held positions in research, quality assurance, and manufacturing at Merck, Insmed, Genzyme Genetics, Terumo BCT, SulzerMedica, and Medtronic. She holds a B.S. in Microbiology from Colorado State University and is a member of the Parenteral Drug Association and Colorado Biosciences Association.

Lane Hapke began his 30+ year career performing contract research and development for membrane separations, first at Bend Research Inc. and then SRI International. He then worked in the pharmaceutical industry at Roche Colorado for over 23 years as a process development engineer, the clinical supply pilot plant manager, and the maintenance and facilities manager.

Hapke directed the site development of Ampio’s single-use manufacturing facilities from the construction phase to equipment, facility, and process validation on a commercial scale. His responsibilities include manufacturing, labeling and packaging, warehousing, shipping and receiving, process development, maintenance and facilities, automation, and information technology.

Hapke obtained his B.S. in Chemical Engineering while riding bulls for the University of Colorado, Boulder, and is a member of the American Institute of Chemical Engineers, the International Society of Pharmaceutical Engineers, the Parental Drug Association, and the North American Membrane Society.